On the Origins of the Androgen Receptor Low Molecular Weight Species

Maria Mudryj, Clifford G Tepper

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Prostate cancer (CaP), a commonly diagnosed malignancy, is readily treated by androgen ablation. This treatment temporarily halts the disease, but castration-resistant neoplasms that are refractory to current therapies emerge. While these neoplasms are no longer dependent on physiological levels of androgens, they remain reliant on the expression of the androgen receptor (AR). There are multiple mechanisms by which CaP cells circumvent androgen ablation therapies. These include AR mutations that broaden ligand specificity, AR overexpression, AR activation by growth factors and cytokines, overexpression of AR co-activators, altered steroid metabolism, and a locus-wide histone transcriptional activation of some AR targets. This review focuses on a more recently described mechanism: the expression of low molecular weight AR species that are missing the ligand-binding domain and function independently of ligand to drive proliferation. The etiology, biological activity, unique features, predictive value, and therapeutic implication of these androgen receptor isoforms are discussed in depth.

Original languageEnglish (US)
Pages (from-to)259-269
Number of pages11
JournalHormones and Cancer
Volume4
Issue number5
DOIs
StatePublished - Oct 2013

Fingerprint

Androgen Receptors
Molecular Weight
Androgens
Ligands
Neoplasms
Castration
Histones
Transcriptional Activation
Prostatic Neoplasms
Intercellular Signaling Peptides and Proteins
Protein Isoforms
Therapeutics
Steroids
Cytokines
Mutation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems

Cite this

On the Origins of the Androgen Receptor Low Molecular Weight Species. / Mudryj, Maria; Tepper, Clifford G.

In: Hormones and Cancer, Vol. 4, No. 5, 10.2013, p. 259-269.

Research output: Contribution to journalArticle

Mudryj, Maria ; Tepper, Clifford G. / On the Origins of the Androgen Receptor Low Molecular Weight Species. In: Hormones and Cancer. 2013 ; Vol. 4, No. 5. pp. 259-269.
@article{5a13db4a4840473881f8efbc756b19a9,
title = "On the Origins of the Androgen Receptor Low Molecular Weight Species",
abstract = "Prostate cancer (CaP), a commonly diagnosed malignancy, is readily treated by androgen ablation. This treatment temporarily halts the disease, but castration-resistant neoplasms that are refractory to current therapies emerge. While these neoplasms are no longer dependent on physiological levels of androgens, they remain reliant on the expression of the androgen receptor (AR). There are multiple mechanisms by which CaP cells circumvent androgen ablation therapies. These include AR mutations that broaden ligand specificity, AR overexpression, AR activation by growth factors and cytokines, overexpression of AR co-activators, altered steroid metabolism, and a locus-wide histone transcriptional activation of some AR targets. This review focuses on a more recently described mechanism: the expression of low molecular weight AR species that are missing the ligand-binding domain and function independently of ligand to drive proliferation. The etiology, biological activity, unique features, predictive value, and therapeutic implication of these androgen receptor isoforms are discussed in depth.",
author = "Maria Mudryj and Tepper, {Clifford G}",
year = "2013",
month = "10",
doi = "10.1007/s12672-013-0152-z",
language = "English (US)",
volume = "4",
pages = "259--269",
journal = "Hormones and Cancer",
issn = "1868-8497",
publisher = "Springer US",
number = "5",

}

TY - JOUR

T1 - On the Origins of the Androgen Receptor Low Molecular Weight Species

AU - Mudryj, Maria

AU - Tepper, Clifford G

PY - 2013/10

Y1 - 2013/10

N2 - Prostate cancer (CaP), a commonly diagnosed malignancy, is readily treated by androgen ablation. This treatment temporarily halts the disease, but castration-resistant neoplasms that are refractory to current therapies emerge. While these neoplasms are no longer dependent on physiological levels of androgens, they remain reliant on the expression of the androgen receptor (AR). There are multiple mechanisms by which CaP cells circumvent androgen ablation therapies. These include AR mutations that broaden ligand specificity, AR overexpression, AR activation by growth factors and cytokines, overexpression of AR co-activators, altered steroid metabolism, and a locus-wide histone transcriptional activation of some AR targets. This review focuses on a more recently described mechanism: the expression of low molecular weight AR species that are missing the ligand-binding domain and function independently of ligand to drive proliferation. The etiology, biological activity, unique features, predictive value, and therapeutic implication of these androgen receptor isoforms are discussed in depth.

AB - Prostate cancer (CaP), a commonly diagnosed malignancy, is readily treated by androgen ablation. This treatment temporarily halts the disease, but castration-resistant neoplasms that are refractory to current therapies emerge. While these neoplasms are no longer dependent on physiological levels of androgens, they remain reliant on the expression of the androgen receptor (AR). There are multiple mechanisms by which CaP cells circumvent androgen ablation therapies. These include AR mutations that broaden ligand specificity, AR overexpression, AR activation by growth factors and cytokines, overexpression of AR co-activators, altered steroid metabolism, and a locus-wide histone transcriptional activation of some AR targets. This review focuses on a more recently described mechanism: the expression of low molecular weight AR species that are missing the ligand-binding domain and function independently of ligand to drive proliferation. The etiology, biological activity, unique features, predictive value, and therapeutic implication of these androgen receptor isoforms are discussed in depth.

UR - http://www.scopus.com/inward/record.url?scp=84884164606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884164606&partnerID=8YFLogxK

U2 - 10.1007/s12672-013-0152-z

DO - 10.1007/s12672-013-0152-z

M3 - Article

C2 - 23860689

AN - SCOPUS:84884164606

VL - 4

SP - 259

EP - 269

JO - Hormones and Cancer

JF - Hormones and Cancer

SN - 1868-8497

IS - 5

ER -